2,2,2-trichloroethyl 2-chloro-2-oxoacetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,2,2-trichloroethyl 2-chloro-2-oxoacetate
• 化学式: C₄H₂Cl₄O₃
• 分子量: 239.87
• InChiKey: VNYMRWBFLDFRJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氟苯 、 2,2,2-trichloroethyl 2-chloro-2-oxoacetate 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 16.5h， 以77%的产率得到2,2,2-trichloroethyl 2-(4-fluorophenyl)-2-oxoacetate
  参考文献：
  名称：

  Synthesis of Donor/Acceptor-Substituted Diazo Compounds in Flow and Their Application in Enantioselective Dirhodium-Catalyzed Cyclopropanation and C–H Functionalization

  摘要：

  A tandem reaction system has been developed for the preparation of donor/acceptor-substituted diazo compounds in continuous flow coupled to dirhodium-catalyzed C-H functionalization or cyclopropanation. Hydrazones were oxidized in flow by solid-supported N-iodo-p-toluenesulfonamide potassium salt (PS-SO2NIK) to generate the diazo compounds, which were then purified by passing through a column of molecular sieves/sodium thiosulfate.

  DOI：

  10.1021/acs.orglett.7b01073
• 作为产物：
  描述：

  草酰氯 、 2,2,2-三氯乙醇 反应 48.0h， 以90%的产率得到2,2,2-trichloroethyl 2-chloro-2-oxoacetate
  参考文献：
  名称：

  Synthesis of Donor/Acceptor-Substituted Diazo Compounds in Flow and Their Application in Enantioselective Dirhodium-Catalyzed Cyclopropanation and C–H Functionalization

  摘要：

  A tandem reaction system has been developed for the preparation of donor/acceptor-substituted diazo compounds in continuous flow coupled to dirhodium-catalyzed C-H functionalization or cyclopropanation. Hydrazones were oxidized in flow by solid-supported N-iodo-p-toluenesulfonamide potassium salt (PS-SO2NIK) to generate the diazo compounds, which were then purified by passing through a column of molecular sieves/sodium thiosulfate.

  DOI：

  10.1021/acs.orglett.7b01073

文献信息

• TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS
  申请人：Cooper Garth James Smith

  公开号：US20130108709A1

  公开（公告）日：2013-05-02

  Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

  药物组合物和治疗方法，用于治疗患有或有风险患有各种疾病、疾病和疾病的受试者，包括线粒体相关疾病、疾病和疾病，包括呼吸链障碍，以及与线粒体肿胀、线粒体功能障碍、线粒体泄漏、氧化应激、线粒体数量增加、线粒体和线粒体相关蛋白质质量增加以及线粒体和相关蛋白质表达增加至少部分有关的疾病、疾病和疾病。
• Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits
  申请人：COOPER Garth James, Smith

  公开号：US20150196500A1

  公开（公告）日：2015-07-16

  Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

  药物组合物和方法，用于治疗患有或有患各种疾病，疾病和疾病的风险，包括与线粒体相关的疾病，疾病和疾病，包括呼吸链疾病，以及与线粒体肿胀，线粒体功能障碍，线粒体泄漏，氧化应激，线粒体数量增加，线粒体和线粒体相关蛋白质质量增加，以及线粒体和相关蛋白质表达增加至少部分相关的疾病，疾病和疾病。
• Copper antagonist compositions
  申请人：Cooper Garth J.S.

  公开号：US20090093542A1

  公开（公告）日：2009-04-09

  Pharmaceutical compositions having a pharmaceutically acceptable copper antagonist(s) or a pharmaceutically acceptable salts or prodrugs thereof, including copper (II) antagonists, and a pharmaceutically acceptable antihypertensive agent or a pharmaceutically acceptable salt or prodrug thereof, articles and kits and delivery devices containing compositions, tablets and capsules and formulations containing such compositions, and methods of use for treatment of subjects, including humans, who have or are at risk for various diseases, disorders, and conditions.
• [EN] COPPER ANTAGONIST COMPOSITIONS<br/>[FR] COMPOSITIONS ANTAGONISTES DU CUIVRE
  申请人：PROTEMIX CORP LTD

  公开号：WO2006104397A1

  公开（公告）日：2006-10-05

  [EN] Pharmaceutical compositions having a pharmaceutically acceptable copper antagonist(s) or a pharmaceutically acceptable salts or prodrugs thereof, including copper (II) antagonists, and a pharmaceutically acceptable anti-obesity agent or a pharmaceutically acceptable salt or prodrug thereof, articles and kits and delivery devices containing compositions, tablets and capsules and formulations containing such compositions, and methods of use for treatment of subjects, including humans, who have or are at risk for various diseases, disorders, and conditions.
  [FR] L'invention se rapporte à des compositions pharmaceutiques ayant un ou plusieurs composé(s) antagoniste(s) du cuivre acceptable(s) du point de vue pharmaceutique ou un sel ou promédicament de ces composés pharmaceutiquement acceptable , incluant des antagonistes du cuivre (II), ainsi qu'un agent anti-obésité ou un sel ou promédicament pharmaceutiquement acceptable de ce dernier, des articles, des kits et des dispositifs de délivrance contenant ces compositions, des comprimés, des gélules et des formulations contenant ces compositions, ainsi que des procédés d'utilisation pour le traitement de sujets, y compris d'humains, qui sont atteints de nombreuses maladies, troubles et états pathologiques ou sont exposés à un risque vis-à-vis de ceux-ci.
• [EN] TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS<br/>[FR] TRAITEMENT DE MALADIES LIÉES AUX MITOCHONDRIES ET AMÉLIORATION DE DÉFICITS MÉTABOLIQUES LIÉS À L'ÂGE
  申请人：PROTEMIX CORP LTD

  公开号：WO2007055598A1

  公开（公告）日：2007-05-18

  [EN] Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction.
  [FR] L'invention concerne un traitement de conditions liées aux mitochondries chez des mammifères aux moyens d'antagonistes ou d'agents chélateurs du cuivre (II), de préférence des tétramines ou des pénicillamines. Lesdits agents affectent le TGF-bêta, le Smad 4, le collagène IV, la cytochrome C oxydase et la dysfonction érectile.